Loss of the predicted cell adhesion molecule MPZL3 promotes EMT and chemoresistance in ovarian cancer.

The article discusses the role of the cell adhesion molecule MPZL3 in ovarian cancer development and progression. It highlights how loss of MPZL3 is associated with epithelial-mesenchymal transition (EMT), decreased proliferation, and drug resistance in ovarian cancer. The study suggests that decreased MPZL3 expression may contribute to treatment failure in advanced-stage ovarian cancer patients. This research has not yet undergone peer review and provides valuable insights into the genetic and immunological aspects of ovarian cancer. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)